全文获取类型
收费全文 | 519篇 |
免费 | 54篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 3篇 |
妇产科学 | 12篇 |
基础医学 | 57篇 |
口腔科学 | 8篇 |
临床医学 | 45篇 |
内科学 | 62篇 |
皮肤病学 | 5篇 |
神经病学 | 34篇 |
特种医学 | 6篇 |
外科学 | 41篇 |
综合类 | 13篇 |
一般理论 | 2篇 |
预防医学 | 121篇 |
眼科学 | 2篇 |
药学 | 48篇 |
肿瘤学 | 112篇 |
出版年
2022年 | 4篇 |
2021年 | 3篇 |
2020年 | 4篇 |
2019年 | 7篇 |
2018年 | 8篇 |
2017年 | 5篇 |
2016年 | 9篇 |
2015年 | 7篇 |
2014年 | 12篇 |
2013年 | 17篇 |
2012年 | 20篇 |
2011年 | 19篇 |
2010年 | 17篇 |
2009年 | 14篇 |
2008年 | 27篇 |
2007年 | 16篇 |
2006年 | 24篇 |
2005年 | 33篇 |
2004年 | 35篇 |
2003年 | 29篇 |
2002年 | 34篇 |
2001年 | 21篇 |
2000年 | 25篇 |
1999年 | 20篇 |
1998年 | 9篇 |
1997年 | 3篇 |
1996年 | 4篇 |
1995年 | 9篇 |
1994年 | 5篇 |
1993年 | 7篇 |
1992年 | 5篇 |
1991年 | 3篇 |
1990年 | 10篇 |
1989年 | 3篇 |
1988年 | 6篇 |
1987年 | 12篇 |
1986年 | 4篇 |
1985年 | 6篇 |
1984年 | 14篇 |
1983年 | 6篇 |
1981年 | 5篇 |
1980年 | 3篇 |
1979年 | 7篇 |
1978年 | 5篇 |
1974年 | 3篇 |
1973年 | 3篇 |
1972年 | 3篇 |
1971年 | 5篇 |
1970年 | 3篇 |
1938年 | 2篇 |
排序方式: 共有573条查询结果,搜索用时 31 毫秒
1.
2.
Patients with medical risk factors for chronic kidney disease are at increased risk of renal impairment despite the use of nephron‐sparing surgery 下载免费PDF全文
3.
An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice 下载免费PDF全文
Miika Ahdesmäki Sally Luke Paul M. Waring Andrew Wallace Ronnie Wright Benno Röthlisberger Katja Ludin Sabine Merkelbach‐Bruse Carina Heydt Marjolijn J.L. Ligtenberg Arjen R. Mensenkamp David Gonzalez de Castro Thomas Jones Ana Vivancos Olga Kondrashova Patrick Pauwels Christine Weyn Eric Hahnen Jan Hauke Richie Soong Zhongwu Lai Brian Dougherty T. Hedley Carr Justin Johnson John Mills J. Carl Barrett 《Human mutation》2018,39(3):394-405
Ovarian cancer patients with germline or somatic pathogenic variants benefit from treatment with poly ADP ribose polymerase (PARP) inhibitors. Tumor BRCA1/2 testing is more challenging than germline testing as the majority of samples are formalin‐fixed paraffin embedded (FFPE), the tumor genome is complex, and the allelic fraction of somatic variants can be low. We collaborated with 10 laboratories testing BRCA1/2 in tumors to compare different approaches to identify clinically important variants within FFPE tumor DNA samples. This was not a proficiency study but an inter‐laboratory comparison to identify common issues. Each laboratory received the same tumor DNA samples ranging in genotype, quantity, quality, and variant allele frequency (VAF). Each laboratory performed their preferred next‐generation sequencing method to report on the variants. No false positive results were reported in this small study and the majority of methods detected the low VAF variants. A number of variants were not detected due to the bioinformatics analysis, variant classification, or insufficient DNA. The use of hybridization capture or short amplicon methods are recommended based on a bioinformatic assessment of the data. The study highlights the importance of establishing standards and standardization for tBRCA testing particularly when the test results dictate clinical decisions regarding life extending therapies. 相似文献
4.
5.
Clinical trials using rapamycin analogues or HER1/epidermal growth factor receptor (EGFR) inhibitors show that each class of agent has activity against a range of human solid tumors. Because blockade of mitogen-activated protein kinase signaling occurs following HER1/EGFR inhibition in some cell types, we tested the combination of rapamycin and erlotinib in SiHa, Me180, and CaSki human cervical carcinomas xenografts in severe combined immunodeficient mice. In tissue culture, all three cell lines showed decreased phosphorylated S6 ribosomal protein and decreased phosphorylated extracellular signal-regulated kinase (ERK) following treatment with rapamycin and erlotinib, respectively. In SiHa tumors, suppression of phosphorylated S6 was induced by either drug alone, whereas phosphorylated ERK decreased with erlotinib, and enhancement of these effects was obtained with the combination. Continuous treatment of xenografts for 3 weeks led to significant tumor growth delay compared with vehicle control for rapamycin as single agent (P = 0.003) and greater for the combination (P = 0.04 versus rapamycin). Significant antiangiogenic effect was obtained in SiHa xenografts using the drugs together (measured by microvascular density and vascular endothelial growth factor plasma levels) but not for the single agents. Me180 and CaSki xenografts showed significant growth delay with rapamycin but not with erlotinib. Erlotinib treatment resulted in decreased phosphorylated ERK, associated with enhanced suppression of phosphorylated S6 and improved growth delay in Me180 but not in CaSki tumors. These results support the further clinical investigation of rapamycin and EGFR inhibitor combinations in anticancer therapy but highlight the problem of intertumoral heterogeneity in the prediction of in vivo response. 相似文献
6.
7.
8.
9.
Romi Goldschlager Hedley Roth Jarryd Solomon Scott Robson Jessica Green Sarah Green Manfred Spanger Robyn Gunn Peter Cameron 《Emergency radiology》2014,21(4):367-372
Current literature suggests that a large proportion of chest X-rays (CXRs) performed in emergency department (ED) patients with chest pain and suspected acute coronary syndrome (ACS) are unnecessary. The Canadian ACS Guidelines aim to guide clinicians in the appropriate use of CXR within this patient population. This study determined the prevalence of clinically significant CXR abnormalities and assessed the utility of the guidelines in a population of ED patients with chest pain and suspected ACS. Included in the study were participants over the age of 18 who presented to an Australian metropolitan ED, over a 1-year period, with a primary complaint of chest pain and who had a CXR and troponin level ordered in the ED (N?=?760). We retrospectively compared their radiographic findings with their recommendations for CXR according to the ACS Guidelines. We found that 12 % of the participants had a clinically significant chest X-ray. The guidelines had a sensitivity of 80 % (95 % CI 0.70–0.87) and specificity of 50 % (95 % CI 0.47–0.54). The positive predictive value was 18 % (95 % CI 0.15–0.22) with a 95 % negative predictive value (95 % CI 0.92–0.97). Had the ACS guidelines been applied to our patient population, the number of CXR performed would have been reduced by 47 %. This study suggests that the ACS Guidelines has the potential to reduce the numbers of unnecessary CXR performed in ED patients. However, this would come at the expense of missing a minority of significant CXR abnormalities. 相似文献
10.
Lorna M Gibson Martha F Hanby Sarah M Al-Bachari Laura M Parkes Stuart M Allan Hedley CA Emsley 《Journal of cerebral blood flow and metabolism》2014,34(4):564-570
The interface between cerebrovascular disease (CVD) and epilepsy is complex and multifaceted. Late-onset epilepsy (LOE) is increasingly common and is often attributed to CVD, and is indeed associated with an increased risk of stroke. This relationship is easily recognizable where there is a history of stroke, particularly involving the cerebral cortex. However, the relationship with otherwise occult, subcortical CVD is currently less well established yet causality is often invoked. In this review, we consider the diagnosis of LOE in clinical practice—including its behaviour as a potential mimic of acute ischemic stroke and transient ischemic attack; evidence for an association between occult CVD and LOE; and potential mechanisms of epileptogenesis in occult CVD, including potential interrelationships between disordered cerebral metabolism and perfusion, disrupted neurovascular unit integrity, blood–brain barrier dysfunction, and inflammation. We also discuss recently recognized issues concerning antiepileptic drug treatment and vascular risk and consider a variety of less common CVD entities associated with seizures. 相似文献